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Abstract
Background: There is a growing body of evidence to support the use of telehealth in monitoring HbA1c levels in
people living with type 2 diabetes. However, the overall magnitude of effect is yet unclear due to variable results
reported in existing systematic reviews. The objective of this study is to conduct a systematic review and meta-
analysis of systematic reviews of randomised controlled trials to create an evidence-base for the effectiveness of
telehealth interventions on glycemic control in adults with type 2 diabetes.
Methods: Electronic databases including The Cochrane Library, MEDLINE, EMBASE, HMIC, and PsychINFO were
searched to identify relevant systematic reviews published between 1990 and April 2016, supplemented by
references search from the relevant reviews. Two independent reviewers selected and reviewed the eligible studies.
Of the 3279 references retrieved, 4 systematic reviews reporting in total 29 unique studies relevant to our review
were included. Both conventional pairwise meta-analyses and network meta-analyses were performed.
Results: Evidence from pooling four systematic reviews found that telehealth interventions produced a small but
significant improvement in HbA1c levels compared with usual care (MD: -0.55, 95% CI: -0.73 to − 0.36). The greatest
effect was seen in telephone-delivered interventions, followed by Internet blood glucose monitoring system
interventions and lastly interventions involving automatic transmission of SMBG using a mobile phone or a
telehealth unit.
Conclusion: Current evidence suggests that telehealth is effective in controlling HbA1c levels in people living with
type 2 diabetes. However there is need for better quality primary studies as well as systematic reviews of RCTs in
order to confidently conclude on the impact of telehealth on glycemic control in type 2 diabetes.
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Background
Diabetes is a serious, chronic condition that is recog-
nised as an important cause of premature death and
disability worldwide. In particular, the prevalence of
type 2 diabetes is emerging as one of the greatest glo-
bal public health challenges in twenty-first century
[1]. In the UK, the National Health Service (NHS)
spends around £9.8 billion a year on diabetes. Most
of this cost (80%) is spent on treating complications
alone as a result of poorly controlled diabetes, of
which many are possibly preventable [2]. These could
include blindness, kidney failure, heart attacks, strokes
and amputations [2]. Diabetes UK warned that “dia-
betes is threatening to bankrupt the NHS after a 60%
rise in cases in the past 10 years”. The cost of treat-
ing diabetes complications is also expected to almost
double by 2035/6 if no actions are taken to prevent
these complications [3]. The urgent need for improve-
ments in effective management of diabetes and pre-
venting its complications is therefore evident.
The aim of diabetes management is to keep blood
sugar levels as close to normal as possible to improve
symptoms and minimise the risk of long-term complica-
tions [4]. This requires close monitoring of vital signs
and effective working relationship between the patient
and their healthcare professionals. The provision of con-
ventional outpatient care alone, which generally occurs
less than 3 times a year [5], is therefore not sufficient.
There is a growing body of evidence that supports
the uses of advanced and innovative technologies,
such as telehealth, to monitor and manage people
with diabetes at a distance and as frequently as it is
needed [5–7]. Telehealth is generally described as the
exchange of medical information from one location to
another using electronic communications or digital
technologies, such as desktop, laptop, mobile phones
and other wireless tools [8].
Overall, existing evidence suggests that telehealth has
the potential in improving HbA1c for patients living
with diabetes but the overall magnitude of effect is un-
clear due to variable results reported in existing system-
atic reviews. Given that the literature already contains
multiple systematic reviews on telehealth and type 2 dia-
betes [7, 9, 10], there is an opportunity to pool the evi-
dence from all existing reviews to report an estimate of
effect. Therefore, to create an evidence base for the ef-
fectiveness of telehealth on glycemic control in type 2
diabetes, we conducted the first systematic review of
systematic reviews and meta-analyses of randomised
controlled trials (RCTs) to assess the evidence of the ef-
fects of telehealth interventions on glycemic control in
patients living with type 2 diabetes.
For the purpose of this study, we defined telehealth as
remote patient monitoring (RPM), which involves the
transmission (electronic or verbal) of self-monitored
blood glucose (SMBG) readings to a healthcare profes-
sional or a specialist team at an offsite monitoring center
for evaluation and feedback.
Methods
Inclusion criteria
Studies that met the following criteria were included in
this review: i) systematic reviews and/or meta-analyses
of RCTs with our definition of telehealth as an interven-
tion; ii) adults ≥18 years of age with a diagnosis of type 2
diabetes; iii) comparison of standard outpatient care
(usual care) or other RPM telehealth interventions; and
iv) reported HbA1c outcome. Systematic reviews and/or
meta-analyses of RCTs on RPM telehealth interventions
were excluded if they: i) were non-English publications;
ii) included a mixed study population (type 1 and type 2
diabetes) and results were not reported separately for
type 2 diabetes; or iii) do not provide feedback to
patients following the transmission of SMBG data. In
systematic reviews where RPM telehealth was one part
of a wider intervention, these were only included where
the effects of the RPM telehealth component were indi-
vidually reported. In addition, if the same authors had
produced several publications of the same review, the
most updated and/or the full report of the review were
included, and other versions excluded.
Search strategy
The literature search was conducted from April 1 to 8,
2016 and the electronic bibliographic databases includ-
ing The Cochrane Library, MEDLINE, EMBASE, HMIC
and PsychINFO were searched. All searches were re-
stricted by date range to 1990 – April 2016. Limiting the
search period from 1990 is likely to identify all apart
from a very small minority of systematic reviews that
were carried out earlier [11, 12]. A base strategy (see
Additional file 1) was developed in MEDLINE (Ovid
interface). This strategy was then converted to run
effectively in other databases using different interfaces.
Reference lists of all potentially relevant systematic
reviews identified by the electronic searches were also
checked for any eligible reviews that have not been
identified in the search.
Study selection and data extraction
Based on the eligibility criteria, two reviewers (AL and
YP) independently screened the list of titles/abstracts
identified through searches for systematic reviews.
Selected systematic reviews at this stage were further
included for a full-text review by the same two re-
viewers. Any disagreements between the reviewers about
the inclusion and exclusion were resolved by discussion
until a consensus was reached. The same two reviewers
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using Eppi-Reviewer software 4 then extracted data from
the resulting final list of selected systematic reviews in-
dependently. The two sets of extracted data were then
compared for quality and validity purposes. Consensus
was achieved without negotiation.
Assessment of risk of bias
The assessment of the methodological quality and
strength of each systematic review was based on the
AMSTAR tool, which is a validated measurement tool
available for evaluating multiple systematic reviews [13].
The AMSTAR tool is a questionnaire that comprises of
11 criteria, which specifically assess the presence of: i)
an a priori design; ii) duplicate study selection and data
extraction; iii) a comprehensive literature search; iv) the
use of status of publication as an inclusion criteria; v) a
list of included/excluded studies; vi) characteristics of in-
cluded studies; vii) documented assessment of the scien-
tific quality of included studies; viii) appropriate use of
the scientific quality in forming conclusions; ix) the ap-
propriate use of methods to combine findings of studies;
x) assessment of the likelihood of publication bias; and
xi) documentation of conflict of interest [14].
Each of the 11 items is given a score of 1 if the specific
criterion is met by a “yes” answer, or a score of 0 if the
criterion is not met, unclear or not applicable. The over-
all AMSTAR score is calculated by adding all the indi-
vidual item scores together. As defined by AMSTAR,
quality is categorised into three levels: high quality if the
total score is between 8 and 11, medium quality if the
total score is between 4 and 7, and low quality if the
total score is between 0 and 3.
The same two reviewers independently assessed each
potentially relevant review for inclusion. Any disagree-
ments between the reviewers were resolved by discus-
sion and when required, a final opinion from a third
reviewer was sought.
Data analysis
To examine the overall magnitude of effect in using tele-
health for controlling HbA1c levels in Type 2 diabetes,
where possible, we conducted conventional pairwise
meta-analyses as well as network meta-analyses (NMAs)
of the included reviews. While the pairwise meta-analyses
allowed us to investigate the difference of effect between
telehealth interventions vs. usual care, the NMAs enabled
us to explore if there is any specific telehealth application
that is superior. NMAs involve the statistical combination
of both direct and indirect evidence about pairs of inter-
ventions that originate from two or more separate studies
to provide estimates of relative effectiveness for all
comparators.
Care was taken to not include data from individual studies
more than once by unpicking each of the included reviews
and the subsequent combination of data of the individual
primary studies included in the reviews. For HbA1c, where
change from baseline data were reported in the trials and
were accompanied by a measure of variation (for example
standard deviation), these were extracted and used in the
meta-analyses. Where measures of spread for change from
baseline values were not reported, these trials were excluded
from the meta-analyses.
Furthermore, due to the various telehealth applications
(technologies) used as well as feedback methods pro-
vided in the interventions, we performed subgroup
meta-analyses to assess whether their impact on gly-
cemic control differed.
The conventional pairwise meta-analyses were con-
ducted with reference to the Cochrane Handbook for
Systematic Reviews, whereas NMAs were undertaken
using the Netmeta package in R3.2.2. This uses a
graph-theoretical method, which is mathematically
equivalent to the frequentist network meta-analysis
[15]. Heterogeneity was assessed using the overall I2
value for the whole network, which is a weighted
average of the I2 value for all comparisons where
there are multiple trials (both direct and indirect),
and random-effects models were used if the I2 value
was above 50% (as for pairwise meta-analyses, this was
interpreted as showing the assumption of a shared under-
lying mean was not met, and therefore a fixed-effects
model was inappropriate). A funnel plot generated in
Review Manager 5 (RevMan 5) for HbA1c was used to
visually assess publication bias.
Items on the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) checklist that is
relevant for a systematic review of reviews was used to
report the findings (see Additional file 2).
Results
Search results
The systematic literature search identified in total 3279
potentially relevant studies. After removing duplicate
studies, 3201 studies were screened on their titles and
abstracts for relevance. In total, 3143 were excluded be-
cause they were not systematic reviews or meta-analyses,
or did not include telehealth interventions or a popula-
tion with diabetes. For the remaining 58 studies, full text
articles were obtained and reviewed against the inclusion
and exclusion criteria. Overall, 54 studies did not meet
the eligibility criteria such as being a systematic review
and/or meta-analysis of RCTs, including telehealth inter-
ventions that met our definition of telehealth, and/or
reporting Type 2 diabetes results separately. These studies
were therefore not included in this review. A detailed list
of excluded studies and reasons for their exclusion is pro-
vided in an additional file (see Additional file 3). Figure 1
provides the systematic review of reviews study flow chart
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that demonstrates the inclusion and exclusion process and
results.
In total, four systematic reviews and/or meta-analyses
met the inclusion criteria and were included in this re-
view. Summaries of these are presented in evidence ta-
bles (see Additional file 4). The included reviews were
published between the years 2009 and 2015. Only one
review conducted meta-analyses [7].
The reviews we included and coded only assessed
studies with an RCT design. Two of the four reviews in-
cluded both type 1 and type 2 diabetes but only data for
type 2 diabetes was used in this review.
Although all four reviews focused on determining the
effectiveness of telehealth applications for individuals
with diabetes, the scopes of the reviews varied. One re-
view solely targeted telehealth remote patient monitor-
ing interventions that incorporated key elements of
structured self-monitoring of blood glucose [16].
Another review only focused on telehealth interventions
in patients with type 2 diabetes and inadequate glycemic
control [7]. For the remaining two reviews, one included
studies using cell phones and wireless devices only [17],
and the other one looked at studies on Internet blood
glucose monitoring systems only [18]. Furthermore, one
of the four reviews only included patients with type 2
diabetes using insulin [18], two reviews included both
insulin- and non-insulin-dependent patients with type 2
diabetes [16, 17] and one review provided no details on
this [7]. The two reviews that included a mixed popula-
tion of insulin- and non-insulin-dependent patients did
not report any results separately for the two groups.
In total, we found 78 studies coded in the four reviews,
of which 51 were considered relevant to our review.
Individual telehealth interventions that were deemed ir-
relevant and excluded included studies that did not in-
volve or report results separately for participants with
type 2 diabetes, studies that did not include telehealth
interventions that met our review’s definition of tele-
health or studies that did not involve the transmission of
SMBG data followed by automatic and/or healthcare
provider feedback. The 51 relevant studies contained 16
duplicates and four studies also had multiple publica-
tions (n = 10); thus, we identified in total 29 unique
studies relevant to our review. However, four of these
studies did not provide extractable data for HbA1c and
were therefore not included in our meta-analyses. The
Fig. 1 PRISMA flow diagram
Lee et al. BMC Health Services Research  (2018) 18:495 Page 4 of 10
number of relevant trials included in each review ranged
from five to 18 trials and the sample sizes of the various
trials ranged widely from 30 to 1665 participants. The
length of the interventions ranged from 3 to 60 months,
with majority of the interventions lasting three months
(13/29 studies) or between six and 12 months (13/29
studies). Only one study reported a five-year follow-up.
Moreover, studies also varied in intervention complex-
ity; nearly half of the studies involved automatic trans-
mission, where self-monitored data are transmitted
directly and automatically to a receiving station without
interruption. This typically involves patients using either
a mobile phone with a diabetes management software
installed and connected to a blood glucose meter or a
telehealth unit that is connected by a secure computer
network at home. Approximately one third of studies
used the Internet or a website to deliver self-monitored
blood glucose results and self-management information.
Lastly, there were also some interventions delivered by
telephone. Telephone-delivered interventions do not re-
quire patients to electronically transmit their daily blood
glucose readings to their healthcare professionals.
Instead, they typically require patients to log their blood
glucose levels daily and a healthcare professional would
follow up with a telephone call weekly to review the
blood glucose log and discuss the glucose values with
the patients.
Moreover, when it came to providing feedback to pa-
tients; majority of the interventions provided feedback at
least once daily, if not more, using one or a combination
of feedback methods including, SMS or text messaging
to the patient’s mobile phone, messaging through inter-
net, telephone calls and/or secure messages via a patient
portal or through a telehealth system. Majority of the
feedback was provided by a healthcare professional but
nearly half of the studies provided automatic feedback
generated from computer algorithms, without provider
input. Only one study utilised videoconferencing as a
way of delivering feedback to patients and three studies
only contacted patients with feedback if necessary (i.e.
when blood glucose levels were not within normal
range). In addition to the wide range of technologies
used, many of the studies also incorporated an educational
component to their telehealth intervention to improve
patients’ knowledge in diabetes self-management.
Almost all studies indicated that the transmitted
self-monitored blood glucose data were used to pro-
vide feedback, or modify treatment or behavior, al-
though the details varied.
For the purposes of subgroup meta-analyses, telehealth
applications and feedback methods were classified into
different categories. For telehealth applications, these were
grouped into four categories according to the method of
transmission used for transmitting self-monitored data to
a receiving station remotely: (i) Internet/web (including
any application or software on a computer or a mobile
phone that uses data networks or the Internet); (ii) auto-
matic transmission (including the use of any telehealth
unit placed at home that automatically and directly
transmit data upon taking measurements); (iii) automatic
mobile transmission (including the use of any telehealth
equipment that allows for the direct transmission of
self-monitored data on the move, without interruption);
and (iv) telephone (interventions delivered by regular tele-
phone calls from a healthcare professional, no electronic
transmission of data involved).
With regards to feedback methods, six categories were
classified: (i) automated message (automated messaging
generated from computer algorithms, without healthcare
provider input); (ii) human calls (interactive telephone
calls with a healthcare provider or researcher); (iii) hu-
man calls only if necessary (i.e. interactive telephone
calls with a healthcare provider only when blood glucose
levels were outside of normal range); (iv) human mes-
sage (personalised feedback via messaging from a health-
care provider); (v) human message + calls (personalised
feedback via messaging from a healthcare provider
followed up by an interactive telephone call); and (vi)
videoconferencing (use of video telecommunication
technologies which allow the patient to communicate in
real-time with a healthcare provider at a distance).
Automated and human messages could include messa-
ging through Internet, SMS, a patient portal and/or a
telehealth system.
Quality assessment of reviews and meta-analyses
Among the four systematic reviews described in the
current review, two were rated moderate quality reviews
[7, 17]. The methodological quality of the remaining two
reviews [16, 18] was considered low according to the
AMSTAR tool (total score of 1 and 2, respectively). The
most common methodological weaknesses were lack of
including an ‘a priori’ design, a list of both included and
excluded studies, and a search for “grey literature or un-
published literature” and/or detail the source of funding/
support for the systematic review and for each of the in-
cluded studies. For the two reviews that scored a low
rating, in addition to the above, the authors did not pro-
vide details on whether they performed duplicate study
selection and data extraction procedures nor include the
use of any quality scoring tool or checklist. Furthermore,
three of the four included reviews were also of qualita-
tive nature; hence further 2 out of the maximum 11
points were lost due to the lack of any statistical pooling
of results and statistical assessment for the presence of
publication bias. The reason for not conducting
meta-analyses in the three qualitative reviews was not
described.
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In the two reviews [7, 17] that used a quality scoring
tool (Downs and Black score and Jadad score, respect-
ively) to assess the scientific quality of their included
RCTs, 18 out of 25 studies were rated as moderate/good
quality. The remaining five RCTs were rated as low qual-
ity based on the Jadad score.
Effectiveness of telehealth interventions in type 2
diabetes
All four reviews primarily examined the effect of tele-
health on HbA1c. Russel-Minda et al., 2008 reported
that three out of their five studies on type 2 diabetes
using cell phones with SMS and Internet (some with
nurse-directed educational component) found a statisti-
cally significant improvement in HbA1c when compared
to usual care. Tildesley et al., 2015 who identified nine
randomised controlled Internet blood glucose monitor-
ing systems (IBGMS) trials, reported that eight of them
showed significantly improved HbA1c levels in the
IBGMS group when compared with the usual care
group. However, one of the studies only achieved signifi-
cant HbA1c reduction at six months but not 12 months.
Greenwood and colleagues (2014) identified and reviewed
16 teleheatlh remote patient monitoring interventions
using one or a combination of technologies (including
telephone, mobile phone, wireless device, telehealth unit
and/or internet), that incorporated key elements of struc-
tured self-monitoring of blood glucose (SMBG) identified
as essential for improving HbA1c. They reported that,
compared to usual care, telehealth was shown to signifi-
cantly improve HbA1c in seven out of the 15 reviewed
studies. The authors also found that interventions that in-
corporated at least five out of the seven key elements of
structured SMBG consistently achieved significant HbA1c
improvements between study groups. In addition, studies
that incorporated at least four of the seven key elements
of structured SMBG and had a baseline HbA1c greater
than 8% resulted in a decrease of at least 0.7% in HbA1c
levels. Lastly, Huang et al., 2015 reported that, compared to
usual care, 11 out of the 18 studies included in the review
found a statistically significant improvement in HbA1c in
the telehealth group. Furthermore, a meta-analysis of the
18 studies found that participants using telehealth had sig-
nificantly improved HbA1c levels when compared to par-
ticipants receiving usual care (MD= − 0.54, 95% CI: -0.75
to − 0.34). The same review also conducted subgroup ana-
lyses that included feedback methods, duration of
follow-up, study location, baseline HbA1c and sample size.
They found that feedback by interactive telephone calls
with a healthcare provider or researcher to be associated
with the greatest improvement in HbA1c (K 1.13; 95% CI,
K 1.51 to K 0.75), followed by automated phone-based
SMS and/or internet-based messaging (K 0.36; 95% CI K
0.47 to O 0.24). No improvement in HbA1c was reported
with automated telephone calls (K 0.01; 95% CI K 0.32 to K
0.29). For the remaining subgroup analyses, a significant re-
duction in HbA1c was reported to be associated with Asian
ethnic groups, small study sample sizes, and patients with a
baseline HbA1c level of 8% or higher.
In order to determine the overall effectiveness of tele-
health on glycemic control in individuals with type 2
diabetes, we conducted additional meta-analyses that in-
corporated all the unique studies, with extractable data
on HbA1c, identified in the four reviews.
A pairwise meta-analysis pooling evidence from 25
(out of 29) RCTs indicate that, compared to usual care,
telehealth is associated with significant improvements in
HbA1c in patients with type 2 diabetes (MD = − 0.55,
95% CI: -0.73 to − 0.36) but with statistical heterogeneity
to the variability in effect estimate (I2 = 82%; Fig. 2). In
addition, although telehealth was statistically better than
usual care in improving HbA1c levels, the confidence
interval of the mean difference crossed the threshold for
minimal clinically important difference (MID) as defined
by the NICE guidelines on type 2 diabetes in adults [19].
The greatest effect was seen in telephone-delivered in-
terventions (MD = − 0.83, 95% CI: -1.54 to − 0.12),
followed by Internet blood glucose monitoring system
interventions (Internet/web) (MD = − 0.77, 95% CI: -1.14
to − 0.40). The effect of automatic data transmission
using a mobile phone or a telehealth unit was shown
to be similar (MD = − 0.27, 95% CI: -0.51 to − 0.03 vs.
MD= − 0.34, 95% CI: -0.48 to − 0.20). Moreover, signifi-
cant heterogeneity was reported in all subgroups except
from the ‘automatic transmission’ subgroup (Fig. 2).
A network meta-analysis of the 25 RCTs further indi-
cated that all telehealth interventions provide a significant
lowering of HbA1c compared with usual care, with Internet
blood glucose monitoring system interventions also provid-
ing significantly more lowering of HbA1c than telehealth
interventions using automatic mobile transmission (MD=
− 0.4934, 95% CI: -0.9250 to − 0.0619). However, consider-
able between-study heterogeneity was present (I2 = 75.3%;
see Additional file 5).
We also conducted pairwise and network meta-analyses
on feedback methods. Evidence from pairwise meta-analyses
of 25 RCTs showed that the human calls subgroup was asso-
ciated with the greatest effect size (MD: -0.98; 95% CI: -1.54
to − 0.42), followed by human message (MD: -0.69; 95% CI:
-1.13 to − 0.26) and then automated message (MD: -0.46;
95% CI: -0.63 to − 0.30) (Fig. 3). Very small effect sizes or no
improvements were reported for feedback via human mes-
sage + calls (n= 1), videoconferencing (n= 1) and human
calls only if necessary (n= 3). This is most likely due to the
very limited number of studies being available in these
subgroups. Similar results were reported in the NMA (see
Additional file 6), where significant reduction in HbA1c
levels was associated human calls, human message and
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automated message subgroups when compared with usual
care groups. In addition, the NMA also suggested that feed-
back provided through human calls and human message to
significantly improve hbA1c levels compared with feedback
provided by healthcare providers only when HbA1c levels
fall outside of normal range (MD: -0.9768, 95% CI: -1.7278
to − 0.2285 and MD: -0.7031, 95% CI: -1.3697 to − 0.0365,
respectively).
Risk of bias
A funnel plot generated in Review Manager assessed
publication bias and significant publication bias towards
positive outcomes in the included studies was observed.
Discussion
Telehealth, which can be defined as personalised health-
care delivered at a distance, is believed to have the po-
tential to enhance the quality of healthcare. Over the
last decade, there have been numerous studies aimed at
assessing the feasibility and effectiveness of telehealth
strategies on the management of diabetes [17]. As the
number of published telehealth studies began to in-
crease, a plethora of systematic reviews on telehealth
interventions of variable scope and quality, also began to
emerge.
Hence, in order to create an evidence-base for the ef-
fectiveness of telehealth on glycemic control in type 2
diabetes specifically, we conducted a review of system-
atic reviews. Moreover, in order to generate precise and
reliable conclusions; we specifically focused on telehealth
applications that involved patients transmitting (elec-
tronically or verbally) SMBG results to a receiving sta-
tion or person to receive automated messages and/or
healthcare provider feedback.
Our systematic literature search identified, in total, 58
potential telehealth and diabetes systematic reviews but
only four reviews met our inclusion criteria, of which
two were of moderate quality and the other two of low
quality according to the AMSTAR tool. All four reviews
concluded that telehealth interventions have the poten-
tial in improving glycemic control in people with type 2
diabetes. However, when we pooled the HbA1c results
from the 25 RCTs included in the four reviews together,
only 14 (56%) studies reported a significant improve-
ment in telehealth intervention versus usual care group.
The greatest improvements in glycemic control with
telehealth was reported in studies where participants
Fig. 2 Pairwise meta-analyses on HbA1c by telehealth applications/ transmission methods
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had a mean baseline HbA1c level of 8% or greater, re-
gardless if they were on insulin or not [7, 16, 18]. These
findings were similar to other recent published system-
atic reviews related to telehealth and diabetes manage-
ment [20–22]. Where study participants had a mean
baseline HbA1c at or near their glycemic target, small
but significant improvements were also reported [18],
suggesting that glycemic improvements with telehealth
is not limited to patients with type 2 diabetes and inad-
equate symptomatic control at baseline (≥8%) only.
It is important to note when interpreting the results
from our review that this review is limited to capturing
and reporting information presented in the included sys-
tematic reviews and meta-analyses. Two important limi-
tations therefore exist in our review of systematic
reviews. Firstly, we depended on the authors of the four
included reviews in this review to have adequately in-
cluded and critically appraised individual studies as well
as correctly captured and interpreted the study results.
We did not examine the full-texts of individual studies
unless there were major data gaps we had to fill in the
reviews or we felt that there may be discrepancies in the
analyses of individual studies included in multiple reviews.
Hence, potential omissions or errors that may be present
in our coding and/or analyses and results, may be due to
unreported errors in the original reviews and/or original
primary studies included in those reviews.
Secondly, the four reviews varied greatly in terms of
the type of telehealth interventions, duration of
follow-up, study sample size, baseline HbA1c levels,
and/or insulin- and non-insulin-dependent population
with type 2 diabetes. In addition, the reviews included
minimal description on the additional telehealth compo-
nents such as e-learning, virtual coach and/or network-
ing support group and how these additional components
may have impacted on the health outcomes. Details on
feedback frequency and how it was used to help support
and improve patient self-management skills were also
limited. In addition, only one of the four reviews con-
ducted meta-analyses. Hence, statistical pooling of
results to assess the estimated mean effect of HbA1c
with telehealth is limited. Although we attempted to
pool and examine the findings on HbA1c from the four
reviews, substantial heterogeneity among individual
studies was evident from the overall meta-analyses, ma-
jority of the subgroup analyses (by transmission and
Fig. 3 Pairwise meta-analyses on HbA1c by telehealth feedback methods
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feedback methods) as well as network meta-analyses due
to the diversity of telehealth interventions and applica-
tions used in the trials. It is therefore difficult to confi-
dently conclude which telehealth component or type 2
diabetes population is likely to benefit the most and
from which telehealth intervention, especially in the
long-term.
We therefore agree with the recommendations made
by the authors of the four reviews that more high qual-
ity, well-designed RCTs with large sample sizes and lon-
ger follow-up durations are needed to investigate the
sustainability and to confirm the benefits of telehealth in
type 2 diabetes management. In addition, to produce re-
liable pooled estimates of HbA1c, it would be useful for
future studies to take into account the differences in
baseline HbA1c level when recruiting study participants
and drawing conclusions from findings. Greenwood et
al., (2014) have also suggested that future telehealth re-
search should explore the use and impact of telehealth on
behavior change in people with non-insulin-dependent
type 2 diabetes. This group of users would primarily use
telehealth for lifestyle and behavior change to manage
their diabetes in contrast to insulin users who would pri-
marily use telehealth for monitoring and adjusting insulin
treatment. Comparing the usage and impact of telehealth
in these two sub populations of diabetes may provide
some explanations as to which and how different tele-
health components work and/or are responsible for im-
proved glycemic control for people with diabetes. For
example, are improvements in HbA1c level with telehealth
dependent on insulin dose adjustments, or SMBG
frequency or from increased self-motivation and/or
patient-physician communication? Future research in this
area could provide important knowledge for clinical prac-
tice for diabetes management [16].
To further strengthen the current evidence-base for tel-
ehealth and the management of type 2 diabetes, future re-
views should also consider assessing the cost-effectiveness
and outcome measures that may influence the uptake and
outcomes of telehealth interventions, such as healthcare
provider satisfaction and patient health-related outcomes
(e.g. quality of life and quality of care) as well as the us-
ability and feasibility of self-monitored devices for diabetes
management. These are all important evidence for current
clinical guidelines and health-related economic policies.
Conclusion
This review found that telehealth interventions produced
a small but significant improvement in HbA1c levels
compared with usual care, suggesting that telehealth has
the potential to deliver beneficial change. However, there
is a need for higher quality primary studies as well as
systematic reviews of RCTs in order for us to draw any
definite conclusions. Furthermore, in order to provide a
complete evidence base for policy makers on the overall
effectiveness of telehealth interventions for type 2 dia-
betes management, future reviews should also focus on
the impact of telehealth in other areas of diabetes man-
agement such as quality of life, quality of care and
cost-effectiveness.
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